Page 581 - Williams Hematology ( PDFDrive )

556 Part VI: The Erythrocyte Chapter 37: Anemia of Chronic Disease 557

38. Kim A, Fung E, Parikh SG, et al: A mouse model of anemia of inflammation: Complex 72. Pascual J, Jimenez C, Franco A, et al: Early-onset anemia after kidney transplantation is
pathogenesis with partial dependence on hepcidin. Blood 123:1129, 2014. an independent factor for graft loss: A multicenter, observational cohort study. Trans-
39. Freireich EM, Miller A, Emerson CP, et al: The effect of inflammation on the utilization plantation 96:717, 2013.
of erythrocyte and transferrin-bound radio-iron for red cell production. Blood 12:972, 73. Jones H, Talwar M, Nogueira JM, et al: Anemia after kidney transplantation; its prev-
1957. alence, risk factors, and independent association with graft and patient survival: A
40. Haurani FI, Burke W, Martinez EJ: Defective reutilization of iron in the anemia of time-varying analysis. Transplantation 93:923, 2012.
inflammation. J Lab Clin Med 65:560, 1965. 74. Kamar N, Rostaing L, Ignace S, et al: Impact of post-transplant anemia on patient
41. O’Shea MJ, Kershenobich D, Tavill AS: Effects of inflammation on iron and transferrin and graft survival rates after kidney transplantation: A meta-analysis. Clin Transplant
metabolism. Br J Haematol 25:707, 1973. 26:461, 2012.
42. Hershko C, Cook JD, Finch CA: Storage iron kinetics. VI. The effect of inflammation on 75. Yabu JM, Winkelmayer WC: Posttransplantation anemia: Mechanisms and manage-
iron exchange in the rat. Br J Haematol 28:67, 1974. ment. Clin J Am Soc Nephrol 6:1794, 2011.
43. Zarrabi MH, Lysik R, DiStefano J, et al: The anaemia of chronic disorders: Studies of 76. Vanrenterghem Y: Anemia after kidney transplantation. Transplantation 87:1265, 2009.
iron reutilization in the anaemia of experimental malignancy and chronic inflamma- 77. Ott U, Busch M, Steiner T, et al: Anemia after renal transplantation: An underestimated
tion. Br J Haematol 35:647, 1977. problem. Transplant Proc 40:3481, 2008.
44. Feldman BF, Kaneko JJ, Farver TB: Anemia of inflammatory disease in the dog: Ferrok- 78. Ghafari A, Noori-Majelan N: Anemia among long-term renal transplant recipients.
inetics of adjuvant-induced anemia. Am J Vet Res 42:583, 1981. Transplant Proc 40:186, 2008.
45. Fillet G, Beguin Y, Baldelli L: Model of reticuloendothelial iron metabolism in humans: 79. Bennett CL, Silver SM, Djulbegovic B, et al: Venous thromboembolism and mortality
Abnormal behavior in idiopathic hemochromatosis and in inflammation. Blood 74:844, associated with recombinant erythropoietin and darbepoetin administration for the
1989. treatment of cancer-associated anemia. JAMA 299:914, 2008.
46. Nicolas G, Bennoun M, Devaux I, et al: Lack of hepcidin gene expression and severe 80. Singh AK, Szczech L, Tang KL, et al: Correction of anemia with epoetin alfa in chronic
tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl kidney disease. N Engl J Med 355:2085, 2006.
Acad Sci U S A 98:8780, 2001. 81. Pfeffer MA, Burdmann EA, Chen CY, et al: A trial of darbepoetin alfa in type 2 diabetes
47. Nicolas G, Bennoun M, Porteu A, et al: Severe iron deficiency anemia in transgenic and chronic kidney disease. N Engl J Med 361:2019, 2009.
mice expressing liver hepcidin. Proc Natl Acad Sci U S A 99:4596, 2002. 82. Solomon SD, Uno H, Lewis EF, et al: Erythropoietic response and outcomes in kidney
48. Nemeth E, Tuttle MS, Powelson J, et al: Hepcidin regulates cellular iron efflux by bind- disease and type 2 diabetes. N Engl J Med 363:1146, 2010.
ing to ferroportin and inducing its internalization. Science 306:2090, 2004. 83. Gaweda AE, Ginzburg YZ, Chait Y, et al: Iron dosing in kidney disease: Inconsistency
49. Hastka J, Lasserre JJ, Schwarzbeck A, et al: Zinc protoporphyrin in anemia of chronic of evidence and clinical practice. Nephrol Dial Transplant 2014 [Epub ahead of print].
disorders. Blood 81:1200, 1993. 84. Ludwig H, Fritz E, Leitgeb C, et al: Prediction of response to erythropoietin treatment
50. Taylor JE, Peat N, Porter C, et al: Regular low-dose intravenous iron therapy improves in chronic anemia of cancer [see comments]. Blood 84:1056, 1994.
response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant 11:1079, 85. Smith RE, Tchekmedyian NS, Chan D, et al: A dose- and schedule-finding study of
1996. darbepoetin alpha for the treatment of chronic anaemia of cancer. Br J Cancer 88:1851,
51. Goodnough LT, Skikne B, Brugnara C: Erythropoietin, iron, and erythropoiesis. Blood 2003.
96:823, 2000. 86. Dammacco F, Castoldi G, Rodjer S: Efficacy of epoetin alfa in the treatment of anaemia
52. Hume R, Currie WJ, Tennant M: Anaemia of rheumatoid arthritis and iron therapy. of multiple myeloma. Br J Haematol 113:172, 2001.
Ann Rheum Dis 24:451, 1965. 87. Hedenus M, Adriansson M, San Miguel J, et al: Efficacy and safety of darbepoetin alfa in
53. Beamish MR, Davies AG, Eakins JD, et al: The measurement of reticuloendothelial iron anaemic patients with lymphoproliferative malignancies: A randomized, double-blind,
release using iron-dextran. Br J Haematol 21:617, 1971. placebo-controlled study. Br J Haematol 122:394, 2003.
54. Brugnara C, Chambers LA, Malynn E, et al: Red blood cell regeneration induced by 88. Peeters HR, Jongen-Lavrencic M, Bakker CH, et al: Recombinant human erythropoi-
subcutaneous recombinant erythropoietin: Iron-deficient erythropoiesis in iron-re- etin improves health-related quality of life in patients with rheumatoid arthritis and
plete subjects [see comments]. Blood 81:956, 1993. anaemia of chronic disease; utility measures correlate strongly with disease activity
55. Gubler CJ, Cartwright GE, Wintrobe MM: The anemia of infection. X. The effect of measures. Rheumatol Int 18:201, 1999.
infection on the absorption and storage of iron by the rat. J Biol Chem 184:563, 1950. 89. Peeters HR, Jongen-Lavrencic M, Vreugdenhil G, et al: Effect of recombinant human
56. Weber J, Werre JM, Julius HW, et al: Decreased iron absorption in patients with active erythropoietin on anaemia and disease activity in patients with rheumatoid arthritis
rheumatoid arthritis, with and without iron deficiency. Ann Rheum Dis 47:404, 1988. and anaemia of chronic disease: A randomised placebo controlled double blind 52
57. Weber J, Julius HW, Verhoef CW, et al: Absorption and retention of iron in rheumatoid weeks clinical trial. Ann Rheum Dis 55:739, 1996.
arthritis. Ann Rheum Dis 32:83, 1973. 90. Goodnough LT, Marcus RE: The erythropoietic response to erythropoietin in patients
58. Nicolas G, Bennoun M, Porteu A, et al: Severe iron deficiency anemia in transgenic with rheumatoid arthritis. J Lab Clin Med 130:381, 1997.
mice expressing liver hepcidin. Proc Natl Acad Sci U S A 99:4596, 2002. 91. Kaltwasser JP, Kessler U, Gottschalk R, et al: Effect of recombinant human erythro-
59. Nicolas G, Chauvet C, Viatte L, et al: The gene encoding the iron regulatory peptide poietin and intravenous iron on anemia and disease activity in rheumatoid arthritis. J
hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 110:1037, Rheumatol 28:2430, 2001.
2002. 92. Schreiber S, Howaldt S, Schnoor M, et al: Recombinant erythropoietin for the treat-
60. Anderson GJ, Frazer DM, Wilkins SJ, et al: Relationship between intestinal iron- ment of anemia in inflammatory bowel disease. N Engl J Med 334:619, 1996.
transporter expression, hepatic hepcidin levels and the control of iron absorption. Bio- 93. Gasche C, Dejaco C, Reinisch W, et al: Sequential treatment of anemia in ulcerative
chem Soc Trans 30:724, 2002. colitis with intravenous iron and erythropoietin. Digestion 60:262, 1999.
61. Roe MA, Collings R, Dainty JR, et al: Plasma hepcidin concentrations significantly 94. Rizzo JD, Lichtin AE, Woolf SH, et al: Use of epoetin in patients with cancer:
predict interindividual variation in iron absorption in healthy men. Am J Clin Nutr evidence-based clinical practice guidelines of the American Society of Clinical Oncol-
89:1088, 2009. ogy and the American Society of Hematology. J Clin Oncol 20:4083, 2002.
62. Young MF, Glahn RP, Riza-Nieto M, et al: Serum hepcidin is significantly associated 95. Rizzo JD, Somerfield MR, Hagerty KL, et al: Use of epoetin and darbepoetin in patients
with iron absorption from food and supplemental sources in healthy young women. with cancer: 2007 American Society of Hematology/American Society of Clinical
Am J Clin Nutr 89:533, 2009. Oncology clinical practice guideline update. Blood 111:25, 2008.
63. Cazzola M, Ponchio L, de Benedetti F, et al: Defective iron supply for erythropoiesis and 96. Rizzo JD, Brouwers M, Hurley P, et al: American Society of Hematology/American
adequate endogenous erythropoietin production in the anemia associated with system- Society of Clinical Oncology clinical practice guideline update on the use of epoetin
ic-onset juvenile chronic arthritis. Blood 87:4824, 1996. and darbepoetin in adult patients with cancer. Blood 116:4045, 2010.
64. Awai M, Brown EB: Studies of the metabolism of I-131-labeled human transferrin. J 97. Drueke TB, Parfrey PS: Summary of the KDIGO guideline on anemia and comment:
Lab Clin Med 61:363, 1963. Reading between the (guide)line(s). Kidney Int 82:952, 2012.
65. Jacobs A, Worwood M: Ferritin in serum. Clinical and biochemical implications. N 98. Macdougall IC, Bock AH, Carrera F, et al: FIND-CKD: A randomized trial of intrave-
Engl J Med 292:951, 1975. nous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and
66. Punnonen K, Irjala K, Rajamaki A: Serum transferrin receptor and its ratio to serum iron deficiency anaemia. Nephrol Dial Transplant 2014.
ferritin in the diagnosis of iron deficiency. Blood 89:1052, 1997. 99. Kapoian T, O’Mara NB, Singh AK, et al: Ferric gluconate reduces epoetin requirements
67. Skikne BS: Serum transferrin receptor. Am J Hematol 83:872, 2008. in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 19:372, 2008.
68. Konz T, Montes-Bayon M, Vaulont S: Hepcidin quantification: Methods and utility in 100. Coyne DW, Kapoian T, Suki W, et al: Ferric gluconate is highly efficacious in anemic
diagnosis. Metallomics 6:1583, 2014. hemodialysis patients with high serum ferritin and low transferrin saturation: Results
69. Goodnough LT, Nemeth E, Ganz T: Detection, evaluation, and management of iron- of the Dialysis Patients’ Response to IV Iron with Elevated Ferritin (DRIVE) Study. J
restricted erythropoiesis. Blood 116:4754, 2010. Am Soc Nephrol 18:975, 2007.
70. Barron BA, Hoyer JD, Tefferi A: A bone marrow report of absent stainable iron is not 101. Jurado RL: Iron, infections, and anemia of inflammation. Clin Infect Dis 25:888, 1997.
diagnostic of iron deficiency. Ann Hematol 80:166, 2001. 102. Oppenheimer SJ: Iron and its relation to immunity and infectious disease. J Nutr
71. Iwamoto H, Nakamura Y, Konno O, et al: Correlation between post kidney transplant 131:616S, 2001.
anemia and kidney graft function. Transplant Proc 46:496, 2014.

Kaushansky_chapter 37_p0549-0558.indd 556 9/17/15 6:17 PM